4SC AG (FRA:VSC)

-67.86% (1Y)

Market Cap	16.20M
Revenue (ttm)	345.00K
Net Income (ttm)	-8.33M
Shares Out	10.91M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450
Average Volume	4,898
Open	1.600
Previous Close	1.760
Day's Range	1.485 - 1.600
52-Week Range	0.400 - 8.960
Beta	1.87
RSI	61.40
Earnings Date	Aug 8, 2025

About 4SC AG

4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany and internationally. The company develops Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma. It also out-licenses and partnered drug candidates to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VSC

Financial Performance

In 2024, 4SC AG's revenue was 345,000, an increase of 13.49% compared to the previous year's 304,000. Losses were -8.33 million, 1.18% more than in 2023.